In PDAC, where SIRT3 downregulation exacerbates metabolic dysregulation and oxidative damage, the combined approach of SIRT3 reactivation and inhibition of oncogenic signaling presents a novel, multifaceted strategy for suppressing cancer progression and improving patient outcomes. Here, SIRT3 is linked to cancer.